he Greek health minister accused Roche (ROG) of blackmail after the drug maker moved to withdraw a cancer drug from the market in response to mandatory discounts imposed by the government.

As part of a bailout deal with its international lenders, such as the European Central Bank and the International Monetary Fund, the Greek government earlier this year imposed a 25 percent levy on sales generated by new patented medicines. And more recently, another 25 percent levy was added on new medicines.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Given that Novartis owns 1/3 of the voting shares in Roche [albeit ‘only 6% of the stock … somehow?], does that mean one should say another pharma is already ‘following suit’? Or not, of course ……

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy